Frédéric Jacotot
Conseiller Juridique Général chez VALNEVA
Fortune : 998 052 $ au 30/04/2024
Profil
Frédéric Jacotot currently works at VALNEVA Austria GmbH, as Co-Managing Director from 2017, Vaccines Holdings Sweden AB, as Director from 2017, Valneva Sweden AB, as Director from 2017, and Valneva SE, as Secretary & General Counsel from 2017.
Mr. Jacotot also formerly worked at Abbott Laboratories, Inc., as Division Counsel from 2010 to 2013.
Mr. Jacotot received his graduate degree from Université Paris 1 Panthéon-Sorbonne.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
VALNEVA SE
0,20% | 31/12/2023 | 276 158 ( 0,20% ) | 998 052 $ | 30/04/2024 |
Postes actifs de Frédéric Jacotot
| Sociétés | Poste | Début |
|---|---|---|
| VALNEVA | Conseiller Juridique Général | 01/04/2017 |
Valneva Sweden AB
 Valneva Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Valneva Sweden AB is a specialty vaccine company that focuses on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The company is based in Solna, Sweden and is primarily focused on marketing and distributing Valneva's vaccines Dukoral®, Ixiaro®, and Kamrab™. Valneva has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and Chikungunya. Additionally, Valneva's portfolio includes two commercial vaccines for travelers. | Directeur/Membre du Conseil | 01/06/2017 |
Vaccines Holdings Sweden AB
 Vaccines Holdings Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Vaccines Holdings Sweden AB develops and distributes vaccines and biological products. The company is based in Solna, Sweden. Franck Charles Marie Grimaud has been the CEO of the Swedish company since 2014. | Directeur/Membre du Conseil | 01/06/2017 |
Valneva Austria GmbH
 Valneva Austria GmbH Miscellaneous Commercial ServicesCommercial Services Part of Valneva SE, VALNEVA Austria GmbH is an Austrian biotechnology company that develops and commercializes vaccines for infectious diseases. The company is based in Vienna, Austria. The CEOs are Thomas Lingelbach, Franck Charles Marie Grimaud, Frédéric Jacotot. The company was founded in 2013. | Directeur Général | 01/09/2017 |
Anciens postes connus de Frédéric Jacotot
| Sociétés | Poste | Fin |
|---|---|---|
Abbott Laboratories, Inc.
 Abbott Laboratories, Inc. Medical SpecialtiesHealth Technology Part of Abbott Laboratories, Inc., the company manufactures and wholesales diagnostic and pharmaceutical products as well as medical devices. The company is based in Chicago, IL. | Corporate Officer/Principal | 01/08/2013 |
Formation de Frédéric Jacotot
| Université Paris 1 Panthéon-Sorbonne | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| VALNEVA | Health Technology |
| Entreprise privées | 4 |
|---|---|
Valneva Austria GmbH
Valneva Austria GmbH Miscellaneous Commercial ServicesCommercial Services Part of Valneva SE, VALNEVA Austria GmbH is an Austrian biotechnology company that develops and commercializes vaccines for infectious diseases. The company is based in Vienna, Austria. The CEOs are Thomas Lingelbach, Franck Charles Marie Grimaud, Frédéric Jacotot. The company was founded in 2013. | Commercial Services |
Vaccines Holdings Sweden AB
Vaccines Holdings Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Vaccines Holdings Sweden AB develops and distributes vaccines and biological products. The company is based in Solna, Sweden. Franck Charles Marie Grimaud has been the CEO of the Swedish company since 2014. | Health Technology |
Abbott Laboratories, Inc.
Abbott Laboratories, Inc. Medical SpecialtiesHealth Technology Part of Abbott Laboratories, Inc., the company manufactures and wholesales diagnostic and pharmaceutical products as well as medical devices. The company is based in Chicago, IL. | Health Technology |
Valneva Sweden AB
Valneva Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Valneva Sweden AB is a specialty vaccine company that focuses on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The company is based in Solna, Sweden and is primarily focused on marketing and distributing Valneva's vaccines Dukoral®, Ixiaro®, and Kamrab™. Valneva has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and Chikungunya. Additionally, Valneva's portfolio includes two commercial vaccines for travelers. | Health Technology |